Quick Answer
SINOVAC BIOTECH LTD reported Total Revenue of $448.27 million for fiscal year 2023.
SINOVAC BIOTECH LTD — Key Financials by Year
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Total Revenue | $448.27M -70.0% |
$1.49B -92.3% |
$19.37B +3694.4% |
$510.62M +107.5% |
$246.05M +7.1% |
$229.65M +31.7% |
| Revenue (ASC 606) | $448.27M -70.0% |
$1.49B -92.3% |
$19.37B +3694.4% |
$510.62M +107.5% |
$246.05M +7.1% |
$229.65M +31.7% |
| Net Income | -$99.92M -187.8% |
$113.87M -98.7% |
$8.47B +7572.0% |
$110.37M +145.7% |
$44.93M +106.3% |
$21.78M -15.6% |
| Diluted EPS | -$1.06 -206.0% |
$1.00 -98.7% |
$74.27 +7556.7% |
$0.97 +136.6% |
$0.41 +20.6% |
$0.34 -24.4% |
| Total Assets | $13.66B -3.2% |
$14.11B -15.7% |
$16.75B +780.9% |
$1.90B +320.4% |
$452.30M +22.3% |
$369.78M +23.6% |
| Cash and Equivalents | $1.27B -70.3% |
$4.28B -63.1% |
$11.61B +1015.2% |
$1.04B +581.7% |
$152.72M -3.4% |
$158.17M +38.2% |
| Stockholders Equity | $8.71B -2.4% |
$8.92B -4.4% |
$9.33B +1149.5% |
$746.47M +153.9% |
$294.02M +16.0% |
$253.43M +67.7% |
| R&D Expense | $344.51M -22.1% |
$442.11M +185.2% |
$155.04M +218.0% |
$48.76M +101.0% |
$24.25M +10.7% |
$21.91M +6.9% |
| Operating Income | -$603.02M -29.4% |
-$466.07M -102.7% |
$17.55B +8039.9% |
$215.64M +214.5% |
$68.56M +51.3% |
$45.32M -0.2% |
| Gross Profit | $266.75M -67.0% |
$808.30M -95.6% |
$18.30B +4027.4% |
$443.44M +107.6% |
$213.58M +4.2% |
$204.93M +33.0% |
| Shares Outstanding | 99.64M +0.1% |
99.50M +0.0% |
99.50M +0.2% |
99.29M +0.4% |
98.90M +39.0% |
71.14M +24.2% |
- SINOVAC BIOTECH LTD reported Total Revenue of $448.27 million for fiscal year 2023.
- SINOVAC BIOTECH LTD showed a decrease of -70.0% in Total Revenue compared to the prior fiscal year.
- SINOVAC BIOTECH LTD reported Revenue (ASC 606) of $448.27 million for fiscal year 2023.
- SINOVAC BIOTECH LTD showed a decrease of -70.0% in Revenue (ASC 606) compared to the prior fiscal year.
- SINOVAC BIOTECH LTD reported Net Income of -$99.92 million for fiscal year 2023.
- SINOVAC BIOTECH LTD showed a decrease of -187.8% in Net Income compared to the prior fiscal year.
- SINOVAC BIOTECH LTD reported Diluted EPS of $1.06 per share (loss) for fiscal year 2023.
- SINOVAC BIOTECH LTD showed a decrease of -206.0% in Diluted EPS compared to the prior fiscal year.
- SINOVAC BIOTECH LTD reported Total Assets of $13.66 billion for fiscal year 2023.
- SINOVAC BIOTECH LTD showed a decrease of -3.2% in Total Assets compared to the prior fiscal year.
- SINOVAC BIOTECH LTD reported Cash and Equivalents of $1.27 billion for fiscal year 2023.
- SINOVAC BIOTECH LTD showed a decrease of -70.3% in Cash and Equivalents compared to the prior fiscal year.
- SINOVAC BIOTECH LTD reported Stockholders Equity of $8.71 billion for fiscal year 2023.
- SINOVAC BIOTECH LTD showed a decrease of -2.4% in Stockholders Equity compared to the prior fiscal year.
- SINOVAC BIOTECH LTD reported R&D Expense of $344.51 million for fiscal year 2023.
- SINOVAC BIOTECH LTD showed a decrease of -22.1% in R&D Expense compared to the prior fiscal year.
- SINOVAC BIOTECH LTD reported Operating Income of -$603.02 million for fiscal year 2023.
- SINOVAC BIOTECH LTD showed a decrease of -29.4% in Operating Income compared to the prior fiscal year.
- SINOVAC BIOTECH LTD reported Gross Profit of $266.75 million for fiscal year 2023.
- SINOVAC BIOTECH LTD showed a decrease of -67.0% in Gross Profit compared to the prior fiscal year.
- SINOVAC BIOTECH LTD reported Shares Outstanding of 99.64 million shares for fiscal year 2023.
- SINOVAC BIOTECH LTD showed an increase of +0.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: